Fishbane S, et al. - In this double-blind, placebo-controlled, phase 3 trial, individuals who underwent hemodialysis who had moderate-to-severe pruritus were randomized to receive either intravenous difelikefalin or placebo three times per week for 12 weeks in order to determine whether difelikefalin were modulating pruritus in conditions like chronic kidney disease. A total of 378 people were randomized. In comparison with those who received a placebo, individuals treated with difelikefalin had a notable decrease in itch intensity and enhanced the itch-related quality of life.